Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
Bioaffinity Technologies, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 15, 2025. The filing serves to announce the issuance of a press release containing financial information for the quarter ended March 31, 2025. The company is classified as an emerging growth company and its common stock and warrants trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that such data is available in the attached press release (Exhibit 99.1), which is not included in the source text provided for analysis.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The filing explicitly states that the financial information is contained within the attached press release, which is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Guidance, Outlook, and Risks
The filing does not provide specific guidance, outlook, management commentary, or risk factors within the main body of the text. It includes a standard disclaimer that the information in Item 2.02 and the attached press release shall not be incorporated by reference into any other SEC filings.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for the actual financial results for the quarter ended March 31, 2025.
- Verify the specific revenue, net income, and cash position figures as they are not present in the 8-K text itself.
- Confirm the status of the company's emerging growth company election and any related accounting standard transitions.
- Check the Nasdaq listing status for both the Common Stock (BIAF) and Tradeable Warrants (BIAFW).